CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SOHO 最新进展与后续问题|老年急性淋巴细胞白血病：低剂量化疗与免疫治疗联合方案
英文原题：SOHO State of the Art Updates and Next Questions|Elderly Acute Lymphoblastic Leukemia: Low-dose chemotherapy and Immunotherapy combinations.
查看英文原题
SOHO State of the Art Updates and Next Questions|Elderly Acute Lymphoblastic Leukemia: Low-dose chemotherapy and Immunotherapy combinations.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
老年急性淋巴细胞白血病（ALL）患者的治疗存在未满足的医疗需求，因为目前抗ALL化疗仅能使少数患者获得长期生存。本文讨论了这些患者近期的管理，包括当前方法和未来方向，因为为难治/复发性ALL开发的新型药物现正被纳入一线治疗，并取得了非常有希望的结果。本文将依次讨论费城染色体（Ph）阴性ALL、Ph+ ALL，最后是T-ALL。相应地，将讨论使用无化疗方法和新药的策略，如inotuzumab ozogamicin、blinatumomab、venetoclax、酪氨酸激酶抑制剂和CAR-T 细胞。
展开英文摘要原文
There is an unmet medical need for the treatment of elderly patients with acute lymphoblastic leukemia (ALL), as only a minority of them achieves long-term survival with current anti-ALL chemotherapy.
Here, the recent management of these patients is discussed, including current approaches and future directions, as novel agents developed for refractory/relapsed ALL are now being incorporated into front-line therapies with very promising results. The manuscript will sequentially consider Philadelphia chromosome (Ph) negative ALL, then Ph+ and finally T-ALL. Accordingly, novel strategies using chemo-free approaches and new drugs such as inotuzumab ozogamicin, blinatumomab, venetoclax, tyrosine kinase inhibitors and CAR T-cells will be discussed.
论文信息
- 作者
- Moyer P、Fourmont AM、Freiman L、Rousselot P、Chevallier P
- 第一作者单位
- Hematology Department, Nantes University Hospital, Nantes, France.France
- 通讯作者单位
- Hematology Department, Nantes University Hospital, Nantes, France; CRCI2NA, INSERM UMR 1307 & CNRS UMR 6075, IRS_UN, University of Nantes, France. Electronic address: patrice.chevallier@chu-nantes.fr.France
- 文献类型
- 综述
- 期刊
- Clinical lymphoma, myeloma & leukemia2025 Nov
- 原文标识
- PubMed 40579283 · DOI 10.1016/j.clml.2025.06.001